ATCC ATCC Logo 0
  • Quick Order
Purple lung cancer cells.

Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Boston Convention and Exhibition Center, Boston, Massachusetts

November 08, 2022 - November 12, 2022

The SITC Annual Meeting brought together a global community of scientists focused on cancer immunotherapy and tumor immunology. Check out our posters from the event and browse our resources below to explore our immuno-oncology research tools, 2-D and 3-D patient-derived cancer models, CAR-T Target Luciferase Reporter Cells, EMT and THP-1 reporter cell lines, human primary cells, cancer panels, and more!

Did you miss us at booth #313 and want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.


Make an appointment

CAR-T cells, CAR-Target, CD19, CD20, HER2

CAR-T Target Luciferase Reporter Cells

Order the reporter cells

Check out our poster presentations

A PD-L1 reporter cell line based on the immune checkpoint protein profiling of ATCC cell lines facilitates cancer immunotherapy drug screening
Hyeyoun Chang, PhD, Scientist, ATCC
November 10, 2022 – November 11, 2022
9:00 AM - 9:00 PM
Abstract Number: 510

Watch the poster presentation

 

Luciferase reporter cancer cell lines facilitate CAR-T development
John Foulke, MS, Lead Biologist, ATCC
November 10, 2022 – November 11, 2022
9:00 AM - 9:00 PM
Abstract Number: 220

Watch the poster presentation

Meet the presenters

Hyeyoun Chang, headshot

Hyeyoun Chang, PhD

Scientist, ATCC

Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School. 

John Foulke, headshot

John Foulke, MS

Lead Biologist, ATCC

John Foulke is a Lead Biologist in the Immuno-Oncology group in the R&D department at ATCC. John joined the ATCC cell biology R&D group in 2008, and he has led many projects centered on the development of novel cell lines and cell-based reporter systems to support cancer research community. His work is mainly focused on developing innovative cell models for research and drug discovery in the immuno-oncology field.

Blue, pink and green IPS organoid cells.

Human Cancer Models Initiative

ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro cancer models representing common as well as rare and understudied examples of cancer from numerous tissues. To enhance their clinical relevance, the sequence data and patient clinical information for each model is available to the research community. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

Find next-generation models

Contact us today!

Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, managing requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.





We will not share your information outside of our distributors network and solely use it to send relevant communications.
Your form has been successfully submitted